Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Tidewater Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.36 (market cap $763.64M), while Tidewater Inc trades at $85.26 (market cap $4.21B). The key difference: Tidewater Inc is far larger — about 5.5× Ginkgo Bioworks Holdings Inc's market cap, and Tidewater Inc is more actively traded (590,005 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Tidewater Inc for 25 Days on average.
| DNA | TDW | |
|---|---|---|
Market Cap | $763.64M | $4.21B |
Volume | 3,204,177 | 590,005 |
Sector | Health | Energy |
52-Week High | $15.83 | $100.61 |
52-Week Low | $5.48 | $47.29 |
Typical Hold Time | 7 Days | 25 Days |
Enterprise Value | $865.59M | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Tidewater (TDW) trades at $85.16, up 2.11% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net margin and 19.49% ROE, though recent earnings missed expectations in Q1 and Q2 2026. The company completed the Wilson Sons Ultratug acquisition in August 2026, enhancing its offshore services footprint. Cash flow remains robust with $252.54M net cash flow in 2025.
Outlook is mixed: analyst consensus targets $105.50 (23.9% upside), but earnings volatility and competitive pressures pose risks. Institutional interest is strong, with BlackRock investing $503.20M in Q2 2026. Investors should weigh solid fundamentals against execution risks in a volatile energy market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
